Floatz logo

Treg Cells

Undifferentiated Leukemia

Masonic Cancer Center, University of MinnesotaCell therapyPhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Undifferentiated Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 3BB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BB
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 3BB
DEXAMETHASONE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BB

View all 50 →

Same molecule, other indications

Treg Cells is also rated in:

myeloproliferative neoplasmDormant
B
Indicative ·
62 / 100
View asset →
chronic myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →
acute lymphoblastic leukemiaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →